<?xml version="1.0" encoding="UTF-8"?>
<ref id="B174-pharmaceuticals-12-00147">
 <label>174.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wei</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Guo</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Tan</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>L.</given-names>
   </name>
  </person-group>
  <article-title>The interaction of cellular protein ANP32A with influenza A virus polymerase component PB2 promotes vRNA synthesis</article-title>
  <source>Arch. Virol.</source>
  <year>2019</year>
  <pub-id pub-id-type="doi">10.1007/s00705-018-04139-z</pub-id>
 </element-citation>
</ref>
